These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 11960387)

  • 1. The ABL tyrosine kinase inhibitor STI571 (Glivec) in Philadelphia positive acute lymphoblastic leukemia - promises, pitfalls and possibilities.
    Ottmann OG; Hoelzer D
    Hematol J; 2002; 3(1):2-6. PubMed ID: 11960387
    [No Abstract]   [Full Text] [Related]  

  • 2. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation.
    Hofmann WK; Jones LC; Lemp NA; de Vos S; Gschaidmeier H; Hoelzer D; Ottmann OG; Koeffler HP
    Blood; 2002 Mar; 99(5):1860-2. PubMed ID: 11861307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia.
    Hofmann WK; Komor M; Wassmann B; Jones LC; Gschaidmeier H; Hoelzer D; Koeffler HP; Ottmann OG
    Blood; 2003 Jul; 102(2):659-61. PubMed ID: 12663457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back.
    von Bubnoff N; Peschel C; Duyster J
    Leukemia; 2003 May; 17(5):829-38. PubMed ID: 12750693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571).
    Scheuring UJ; Pfeifer H; Wassmann B; Bruck P; Atta J; Petershofen EK; Gehrke B; Gschaidmeier H; Hoelzer D; Ottmann OG
    Blood; 2003 Jan; 101(1):85-90. PubMed ID: 12393581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chronic myeloid leukemia and tyrosine kinase inhibitors].
    Mahon FX
    Rev Med Interne; 2001 Sep; 22(9):894-9. PubMed ID: 11599196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. As leukemia options grow, drugs jockey to be first-line therapies.
    Dolgin E
    Nat Med; 2013 Jan; 19(1):7. PubMed ID: 23295994
    [No Abstract]   [Full Text] [Related]  

  • 8. STI571 (Gleevec) as a paradigm for cancer therapy.
    Druker BJ
    Trends Mol Med; 2002; 8(4 Suppl):S14-8. PubMed ID: 11927282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia.
    O'Dwyer ME; Druker BJ
    Lancet Oncol; 2000 Dec; 1():207-11. PubMed ID: 11905636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukemia/lymphoma caused by P190 Bcr/Abl.
    Mishra S; Zhang B; Groffen J; Heisterkamp N
    Leukemia; 2004 Jan; 18(1):23-8. PubMed ID: 14603339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Stock W
    Leuk Lymphoma; 2010 Feb; 51(2):188-98. PubMed ID: 20001232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic myelogenous leukaemia--new therapeutic principles.
    O'Dwyer ME; Druker BJ
    J Intern Med; 2001 Jul; 250(1):3-9. PubMed ID: 11454136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.
    Ottmann OG; Druker BJ; Sawyers CL; Goldman JM; Reiffers J; Silver RT; Tura S; Fischer T; Deininger MW; Schiffer CA; Baccarani M; Gratwohl A; Hochhaus A; Hoelzer D; Fernandes-Reese S; Gathmann I; Capdeville R; O'Brien SG
    Blood; 2002 Sep; 100(6):1965-71. PubMed ID: 12200353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment with dasatinib and allogeneic peripheral blood stem cell transplant for imatinib-resistant Philadelphia chromosome-positive acute lymphoblastic leukemia relapsing after bone marrow transplant and donor lymphocyte infusion.
    Tachibana T; Numata A; Tanaka M; Motohashi K; Fujisawa S; Fujita H; Sakai R; Tomita N; Maruta A; Ishigatsubo Y; Kanamori H
    Leuk Lymphoma; 2011 Jul; 52(7):1376-9. PubMed ID: 21438838
    [No Abstract]   [Full Text] [Related]  

  • 15. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
    Pfeifer H; Wassmann B; Pavlova A; Wunderle L; Oldenburg J; Binckebanck A; Lange T; Hochhaus A; Wystub S; Brück P; Hoelzer D; Ottmann OG
    Blood; 2007 Jul; 110(2):727-34. PubMed ID: 17405907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STI571 (imatinib mesylate): the tale of a targeted therapy.
    Thambi P; Sausville EA
    Anticancer Drugs; 2002 Feb; 13(2):111-4. PubMed ID: 11901302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. STI571: a gene product-targeted therapy for leukemia.
    Mauro MJ; Druker BJ
    Curr Oncol Rep; 2001 May; 3(3):223-7. PubMed ID: 11296132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Jeha S; Coustan-Smith E; Pei D; Sandlund JT; Rubnitz JE; Howard SC; Inaba H; Bhojwani D; Metzger ML; Cheng C; Choi JK; Jacobsen J; Shurtleff SA; Raimondi S; Ribeiro RC; Pui CH; Campana D
    Cancer; 2014 May; 120(10):1514-9. PubMed ID: 24501014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors].
    Thomas X
    Bull Cancer; 2007 Oct; 94(10):871-80. PubMed ID: 17964981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.